General information about company
Scrip code*		523144
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE442D01010
Name of company		MEDI-CAPS LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2024
Date of end of financial year		31-03-2025
Date of board meeting when results were approved		21-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		14-05-2025
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Fourth quarter
Nature of report standalone or consolidated		Standalone
Whether results are audited or unaudited for the quarter ended		Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Audited
Segment Reporting		Single segment
Description of single segment		REAL ESTATE
Start date and time of board meeting		21-05-2025 15:00
End date and time of board meeting		21-05-2025 15:45
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion
Whether the company has any related party?		Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public		NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank’s staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		NA
(III) Whether the company is a ‘high value debt listed entity’ according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		12-02-2025
Indicate Company website link for updated RPT policy of the Company		https://www.medicaps.com/upload/RPT%20Policy_Medicaps.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	There was no default on Loans and Debt Securities

Financial Results – Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	89.08	241.66
	Other income	26.91	56.25
	Total income	115.99	297.91
2	Expenses
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.17	0.45
(d)	Employee benefit expense	44.91	181.05
(e)	Finance costs	0	0
(f)	Depreciation, depletion and amortisation expense	4	16.01
(g)	Other Expenses
1	Power cost	0.27	0.49
2	Fright Exp.	0	0
3	Other Expenses	23.04	71.41
	Total other expenses	23.31	71.9
	Total expenses	72.39	269.41
3	Total profit before exceptional items and tax	43.6	28.5
4	Exceptional items	0	0
5	Total profit before tax	43.6	28.5
6	Tax expense
7	Current tax	-25.56	-25.56
8	Deferred tax	-1.45	-1.45
9	Total tax expenses	-27.01	-27.01
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	70.61	55.51
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	70.61	55.51
17	Other comprehensive income net of taxes	-25.36	29.95
18	Total Comprehensive Income for the period	45.25	85.46
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	1247	1247
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve		5487.39
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.57	0.45
	Diluted earnings (loss) per share from continuing operations	0.57	0.45
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)
	Basic earnings (loss) per share from continuing and discontinued operations	0.57	0.45
	Diluted earnings (loss) per share from continuing and discontinued operations	0.57	0.45
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)

Text Block

Textual Information(4)

NOTES:

1. The above standalone and consolidated Audited financial results for the Quarter and Financial Year ended March 31, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on May 21, 2025. The statutory auditors have expressed an unmodified opinion for financial results for the year ended 31st March,2025 therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above consolidated results included the results of the wholly owned subsidiary company i.e. Medgel Private Limited.

4. The Company has two reportable segments for the Consolidated Financial Statements which consists of the Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and the same is enclosed with this result.

5. The standalone and consolidated statement of assets & Liabilities as at March 31, 2025 is annexed with the results along with cash flow statements.

6. The Company has generated revenue of Rs. 89.08 Lacs during this quarter and Rs. 241.66 Lacs during F.Y. 2024-25 from sales of shops at Medicaps Business Park

7. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.

8. The Statement includes the results for the quarters ended March 31, 2025 and March 31, 2024 and being the balancing figure of the audited figures in respect of the full financial year ended March 31, 2025 and March 31, 2024 and the published year to date figures upto the third quarter of the respective financial years, the results of which were subjected to ‘limited review’.

9. The aforesaid audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.

DATE: 21.05.2025 For and on behalf of the Board of Directors of
PLACE: INDORE MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	209.64
	Capital work-in-progress	7.58
	Investment property	0
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	4390.47
	Trade receivables, non-current
	Loans, non-current	0
	Other non-current financial assets
	Total non-current financial assets	4390.47
	Deferred tax assets (net)
	Other non-current assets	4.92
	Total non-current assets	4612.61
2	Current assets
	Inventories	2.71
	Current financial asset
	Current investments	1297.99
	Trade receivables, current	366.4
	Cash and cash equivalents	5.24
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	0
	Total current financial assets	1669.63
	Current tax assets (net)	0
	Other current assets	517.71
	Total current assets	2190.05
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	6802.66
	Total current assets	2190.05
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	6802.66
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	1247
	Other equity	5487.39
	Total equity attributable to owners of parent	6734.39
	Non controlling interest
	Total equity	6734.39
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade Payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities
	Total non-current financial liabilities	0
	Provisions, non-current	0
	Deferred tax liabilities (net)	41.45
	Deferred government grants, Non-current
	Other non-current liabilities
	Total non-current liabilities	41.45
	Current liabilities
	Current financial liabilities
	Borrowings, current	0
	Trade Payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	4.03
	Total Trade payable	4.03
	Other current financial liabilities
	Total current financial liabilities	4.03
	Other current liabilities	22.79
	Provisions, current	0
	Current tax liabilities (Net)
	Deferred government grants, Current
	Total current liabilities	26.82
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	68.27
	Total equity and liabilities	6802.66
	Disclosure of notes on assets and liabilities	Textual Information(1)

Other Comprehensive Income
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified to statement of profit & loss	-25.36	29.95
	Total Amount of items that will not be reclassified to profit and loss	-25.36	29.95
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified to statement of profit & loss	0.00	0.00
	Total Amount of items that will be reclassified to profit and loss	0.00	0.00
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	-25.36	29.95

Cash flow statement, indirect
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.
1	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax	28.5
2	Adjustments for reconcile profit (loss)
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	0.45
	Adjustments for decrease (increase) in trade receivables, current	98.64
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	0
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	76.91
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	0
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-90.58
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	16.01
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	29.95
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	131.38
	Net cash flows from (used in) operations	159.88
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	-25.56
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	185.44
3	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	177.62
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	7.12
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	-184.74
4	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	0
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0.7
5	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	0.7
	Cash and cash equivalents cash flow statement at beginning of period	4.54
	Cash and cash equivalents cash flow statement at end of period	5.24

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Sr. No.

Details of the party (listed entity /subsidiary) entering into the transaction

Details of the counterparty

Type of related party transaction

Details of other related party transaction

Value of the related party transaction as approved by the audit committee

Remarks on approval by audit committee

Value of the related party transaction ratified by the audit committee

Date of Audit Committee Meeting where the ratification was approved

Value of transaction during the reporting period

In case monies are due to either party as a result of the transaction

In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments

Details of the loans, inter-corporate deposits, advances or investments

Name

PAN

Name

PAN

Relationship of the counterparty with the listed entity or its subsidiary

Opening balance

Closing balance

Nature of indebtedness (loan/ issuance of debt/ any other etc.)

Details of other indebtedness

Cost

Tenure

Nature (loan/ advance/ intercorporate deposit/ investment)

Interest Rate (%)

Tenure

Secured/ unsecured

Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)

Notes

MEDI-CAPS LIMITED

AABCM1905G

HEMANT SETHI

CJQPS4931M

CFO

Remuneration

APPROVE BY AUDIT COMMITTEE

7.38

0.55

1.65

MEDI-CAPS LIMITED

AABCM1905G

ABHISHEK JAIN

BYWPK5427J

COMPANY SECRETARY & COMPLIANCE OFFICER

Remuneration

APPROVE BY AUDIT COMMITTEE

3.48

0.57

MEDI-CAPS LIMITED

AABCM1905G

ALOK K. GARG

AAHPG5352J

PROMOTER AND KMP (MD) OF THE COMPANY

Remuneration

APPROVE BY AUDIT COMMITTEE

MEDI-CAPS LIMITED

AABCM1905G

AKSHIT GARG

BSJPG4756K

General Manager & Relative of KMP of the company

Remuneration

APPROVE BY AUDIT COMMITTEE

2.5

MEDI-CAPS LIMITED

AABCM1905G

SALONI GARG

AFUPA8271L

Senior Manager & Relative of KMP of the company

Remuneration

APPROVE BY AUDIT COMMITTEE

MEDI-CAPS LIMITED

AABCM1905G

MEDICAPS CHARITABLE TRUST

AABTM1123F

ENTITY OVER WHICH DIRECTORS SIGNIFICANT INFLUENCE

Any other transaction

RENT RECEIVED

APPROVE BY AUDIT COMMITTEE

MEDI-CAPS LIMITED

AABCM1905G

YOGITA SETHI

FTYPS2791Q

RELATIVE OF CFO

Any other transaction

CONSULTANCY

APPROVE BY AUDIT COMMITTEE

3.52

MEDGEL PRIVATE LIMITED

AAECM9146J

MRS. MANISHA GARG

ADOPG7990A

Person belonging to promoter group and KMP (WTD) of wholly owned subsidiary Company

Remuneration

36.65

APPROVE BY AUDIT COMMITTEE

18.65

Remuneration (Including incentives within permissible limit)

MEDGEL PRIVATE LIMITED

AAECM9146J

MR. PRAVEEN NALWAYA

ACZPN7157N

KMP (WTD) of wholly owned subsidiary Company

Remuneration

APPROVE BY AUDIT COMMITTEE

28.91

4.62

MEDGEL PRIVATE LIMITED

AAECM9146J

MR. LOKESH PARMAR

BMSPP3821P

Chief Financial Officer of wholly owned subsidiary Company

Remuneration

APPROVE BY AUDIT COMMITTEE

4.88

0.71

0.8

MEDGEL PRIVATE LIMITED

AAECM9146J

VAIBHAV SINGHAI

BEQPS8022D

Company Secretary of wholly owned subsidiary Company

Remuneration

APPROVE BY AUDIT COMMITTEE

2.02

0.33

MEDGEL PRIVATE LIMITED

AAECM9146J

MRS. SANDHYA NALWAY

AAOPN9487C

Manager & Relative of KMP of wholly owned subsidiary

Remuneration

APPROVE BY AUDIT COMMITTEE

11.53

1.78

2.1

MEDGEL PRIVATE LIMITED

AAECM9146J

MR. PALASH GARG

CQIPG1108H

Vice President & Relative of KMP of wholly owned subsidiary Company

Remuneration

APPROVE BY AUDIT COMMITTEE

0.5

MEDI-CAPS LIMITED

AABCM1905G

MEDGEL PRIVATE LIMITED

AAECM9146J

Wholly owned Subsidiary

Investment

4282.35

MEDI-CAPS LIMITED

AABCM1905G

MEDGEL PRIVATE LIMITED

AAECM9146J

Wholly owned Subsidiary

Sale of goods or services

0.46

APPROVE BY AUDIT COMMITTEE

0.46

Total value of transaction during the reporting period

152.83

Details of Impact of Audit Qualification
Whether results are audited or unaudited		Audited
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015:The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Rawka & Associates	Yes	28-02-2026

General information about company

Financial Results – Ind-AS

Text Block

Statement of Asset and Liabilities

Other Comprehensive Income

Cash flow statement, indirect

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Details of Impact of Audit Qualification